Loading
AB
Arbutus Biopharma Corporation Stock: price and insider trades · Canada
Arbutus Biopharma Corporation: what insiders have been doing
Arbutus Biopharma Corporation is a listed company. Its directors and officers file their transactions with SEDI. Between 18 October 2025 and 18 October 2026, 5 insiders published 20 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
No insider has bought Arbutus Biopharma Corporation shares on the open market in the past twelve months. The median gap between a trade and its publication by SEDI is 5 days. Until a filing is published, the market cannot know about the trade.
Compared with its exchange (2,130 companies, median 12 filings), a count of 20 filings is above the norm.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
20
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 7 October 2026
Declarations20 total
17,948 shares@ CA$5.006.3% of flowCommon SharesTSXSEDI:4789070
48,081 shares@ CA$5.0010.3% of flowCommon SharesTSXSEDI:4789068
17,142 shares@ CA$5.006.4% of flowCommon SharesTSXSEDI:4789067
24,655 shares@ CA$5.0012.8% of flowCommon SharesTSXSEDI:4789065
8,967,383 shares@ CA$5.00100.0% of flowCommon SharesTSXSEDI:4788522
99,057 shares@ CA$5.070.037% mcap37.5% of flowCommon SharesTSXSEDI:4780969
52,533 shares@ CA$3.200.012% mcap12.6% of flowOptionsTSXSEDI:4780963
78,800 shares@ CA$4.240.024% mcap25.0% of flowOptionsTSXSEDI:4780962
82,525 shares@ CA$5.070.031% mcap33.2% of flowCommon SharesTSXSEDI:4780960
Common SharesTSXSEDI:4780956
52,533 shares@ CA$3.340.013% mcap13.9% of flowOptionsTSXSEDI:4780955
78,800 shares@ CA$4.240.024% mcap26.5% of flowOptionsTSXSEDI:4780954
82,527 shares@ CA$5.070.031% mcap50.0% of flowCommon SharesTSXSEDI:4780949
10,456 shares@ CA$4.390.0034% mcap5.5% of flowOptionsTSXSEDI:4780945
116,408 shares@ CA$3.200.027% mcap44.5% of flowOptionsTSXSEDI:4780944
206,637 shares@ CA$5.070.077% mcap50.0% of flowCommon SharesTSXSEDI:4780943
27,475 shares@ CA$4.390.0088% mcap5.8% of flowOptionsTSXSEDI:4780940
265,625 shares@ CA$3.490.068% mcap44.2% of flowOptionsTSXSEDI:4780939
78,800 shares@ CA$4.2426.4% of flowOptionsTSXSEDI:4734084
78,800 shares@ CA$4.2424.9% of flowOptionsTSXSEDI:4734081
20 of 20 declarations
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing treatments for viral infections, particularly hepatitis B. It is listed on the Toronto Stock Exchange under the symbol ABUS.
